Bank of America downgraded Bristol-Myers Squibb BMY from Buy to Neutral and raises the price objective from $38.00 to $39.00.
Bank of America noted, "[W]ith the stock now at ~$37 (P/E on ‘13E of 20.6x vs. avg. of 14.2x), we do not see enough total return potential to justify a Buy rating. We remain constructive on BMY with its solid dividend yield (3.8%) and pipeline optionality. Launch progress for Eliquis will be important for the stock in the near/medium term. We are increasing our PO to $39 (from $38) following our model updates and an increased peak sales estimate for nivolumab."
Bristol-Myers Squibb closed at $37.15 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in